Medicare Drug Coding Drops Six-Month Marketing Requirement
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes to the HCPCS coding process for Part B drugs are issued by the Centers for Medicare & Medicaid Services' Council on Technology & Innovation. The changes will be phased in over 18 months beginning with the 2006 coding cycle.
You may also be interested in...
CMS Ready To Unveil "Council For Technology & Innovation"
The council will establish two working groups: the "Better Evidence" group will focus on improving clinical data available for coverage decisions and the "Effective Innovation" group will develop ways to improve the efficiency of the coverage decision process. CMS' Herbert Kuhn and Sean Tunis will co-chair the council.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.